Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced non-small cell lung cancer
Lung Cancer, 04/26/2012
Clinical Article
Ahn MJ et al. – East Asian never–smoker patients with advanced NSCLC and unknown epidermal growth factor receptor mutation status had improved progression–free survival following treatment with first–line PC and sequential G. Irrespective of subsequent maintenance treatment, induction PC was safe and efficacious, leading to prolonged OS in the Asian patient population.



